Abstract: A method for subsurface sequestration of carbon includes injecting a treatment composition comprising a mineralization accelerant into a subterranean zone at least partially saturated with saline water. The mineralization accelerant is reactive with carbon dioxide to form bicarbonate. The method further includes injecting carbon in the form of carbon dioxide into the subterranean zone and sequestering at least a portion of the carbon in the subterranean zone by precipitation in the subterranean zone of a carbonate mineral formed from reaction of the bicarbonate with metal cations dissolved in the saline water. At least a portion of the bicarbonate is formed by reaction of the mineralization accelerant with the carbon dioxide.

Abstract: A defect centre-based sensor is disclosed. The sensor comprises instrumentation which includes a generator for causing excitation in an active element, for example a diamond, and a detector for measuring a transition in the active element. The generator is an optical source and/or the detector is an optical detector. The sensor further comprises an optical waveguide and a sensor head in communication with the source and/or the detector via the optical waveguide. The sensor head houses the active element having at least one defect centre, for example, a nitrogen vacancy, responsive to an applied magnetic field, electric field or temperature and a signal delivery arrangement, for example at least one lens, arranged to optically couple the optical waveguide to the active element.

Abstract: Sensor A device is disclosed. The device comprises a magnet (15) arranged to apply an inhomogeneous magnetic field (B) to a given volume (16) and a magnetometer having an active element (8) for sensing magnetic field in a volume which includes the given volume (16).

Abstract: The invention provides implantable drug delivery devices comprising a core comprising a polymer (or polymer blend) and one or more drugs or pharmaceutical substances, and an outer shell comprising a polymer (or polymer blend) and one or more porogen materials. The invention reduces burst release of drug. Pharmaceuticals such as triiodothyronine (T3) or ropinirole can be delivered by the devices.

Abstract: An aqueous personal care composition comprising: one or more amphoacetates; one or more glutamate surfactants selected from sodium lauroyl glutamate, dipotassium cocoyl glutamate, potassium lauryl/myristoyl glutamate and combinations thereof; and cocamide MIPA; wherein the composition is free of sulfates and ethoxylates.

Abstract: The invention provides implantable drug delivery devices comprising a core comprising a polymer (or polymer blend) and one or more drugs or pharmaceutical substances, and an outer shell comprising a polymer (or polymer blend) and one or more porogen materials. The invention reduces burst release of drug. Pharmaceuticals such as triiodothyronine (T3) or ropinirole can be delivered by the devices.

Abstract: A system and method for finding an optimum travel plan for several subsequent destinations. The system can receive several destinations from the user and determine the optimum travel plan. The different destinations can be provided by capturing an address or location from a webpage or uploading an image of the destination.

Abstract: The present application provides processes for the purification of ferric carboxymaltose, the process includes the steps of dissolving crude ferric carboxymaltose in a first solvent; charging the ferric carboxymaltose solution in a reaction vessel with a second solvent and precipitating therefrom a ferric carboxymaltose precipitate; and isolating pure ferric carboxymaltose from the ferric carboxymaltose precipitate.

Abstract: The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time. Buprenorphine is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with buprenorphine.

Abstract: A defect centre-based sensor is disclosed. The sensor comprises instrumentation which includes a generator for causing excitation in an active element, for example a diamond, and a detector for measuring a transition in the active element. The generator is an optical source and/or the detector is an optical detector. The sensor further comprises an optical waveguide and a sensor head in communication with the source and/or the detector via the optical waveguide. The sensor head houses the active element having at least one defect centre, for example, a nitrogen vacancy, responsive to an applied magnetic field, electric field or temperature and a signal delivery arrangement, for example at least one lens, arranged to optically couple the optical waveguide to the active element.

Abstract: The present invention relates to a disinfection passageway with an alerting system. The passageway includes: a first sidewall; a second sidewall; and a top cover extending between the first sidewall and the second sidewall. The passageway also has a storage tank attached to the outer surface of the first sidewall. The storage tank stores sanitizing liquid for dispensing through a plurality of nozzles on the inner surface of at least one sidewall. A temperature sensor is also attached to the passageway, wherein the temperature sensor is adapted for measuring a body temperature of a user. Finally, a hand sanitizer dispenser on the inner surface of at least one side wall adapted for dispensing hand sanitizer.

Abstract: The present application provides processes for the purification of ferric carboxymaltose, the process includes the steps of dissolving crude ferric carboxymaltose in a first solvent; charging the ferric carboxymaltose solution in a reaction vessel with a second solvent and precipitating therefrom a ferric carboxymaltose precipitate; and isolating pure ferric carboxymaltose from the ferric carboxymaltose precipitate.

Abstract: The present application provides methods for the synthesis of intermediates in the synthesis of Safinamide or a pharmaceutically acceptable salt thereof herein Safinamide Mesylate, that is substantially free of impurities.

Abstract: A system and method for finding an optimum travel plan for several subsequent destinations. The system can receive several destinations from the user and determine the optimum travel plan. The different destinations can be provided by capturing an address or location from a webpage or uploading an image of the destination.

Abstract: Loadable porous structures are disclosed, which are structures with pre-formed pores. The loadable porous structures can be loaded with pharmaceutical substances and optional excipients. The loaded porous structures can then be used as implants, for implantation into a patient for release of pharmaceutical substances over long periods of time. Methods of making and using such structures and implants are also disclosed.

Abstract: An online/electronic platform for hosting images, wherein the online platform can associate the images to the geographical address at which the images are taken and the time at which the images are taken. The disclosed platform provides an interface on an electronic device to upload images to the online platform. The interface may also allow a user to capture the images for uploading to the online platform.

Abstract: The present application generally provides ferric maltol of formula I, and more particularly a crystalline form alfa of Ferric maltol, which is characterized by its PXRD pattern as illustrated herein. Corresponding methods for producing the ferric maltol disclosed herein are also provided.

Abstract: Implants are described which comprise lipophilic pharmaceutical substances. Excipients are used which provide appropriate and controllable/tunable release of the lipophilic drug from the matrix of the implant. The implants can be implanted into a patient for release of the pharmaceutical substances. Methods of making and using such implants are also described.

Abstract: The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time. Buprenorphine is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with buprenorphine.

Abstract: The present application provides methods for the synthesis of intermediates in the synthesis of Safinamide or a pharmaceutically acceptable salt thereof herein Safinamide Mesylate, that is substantially free of impurities.